| Unknown | Feasibility of a New Technology for Isolating Circulating Tumour Cells NCT03979339 | Centre Oscar Lambret | N/A |
| Withdrawn | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT02966587 | University of Washington | Phase 2 |
| Active Not Recruiting | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer NCT02881242 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT02844582 | University of California, Davis | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Completed | Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer NCT03122743 | Wake Forest University Health Sciences | — |
| Terminated | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies NCT02985021 | Seattle Institute for Biomedical and Clinical Research | Phase 2 |
| Terminated | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer NCT02516670 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients NCT02853097 | University of Southern California | — |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO NCT04516707 | Institut du Cancer de Montpellier - Val d'Aurelle | — |
| Withdrawn | Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With NCT02169063 | University of Washington | N/A |
| Terminated | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant P NCT02491411 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Terminated | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistan NCT02429804 | Stanford University | Phase 1 |
| Completed | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cance NCT02159950 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or NCT02370355 | University of Southern California | — |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated Wit NCT02312557 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-R NCT02215161 | University of California, San Francisco | Phase 2 |
| Completed | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer NCT02184533 | Stanford University | Phase 1 |
| Unknown | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metasta NCT01949337 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer NCT02012296 | University of Chicago | Phase 1 / Phase 2 |
| Terminated | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01866423 | University of Southern California | Phase 2 |
| Completed | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT01848067 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel- NCT01833208 | Roswell Park Cancer Institute | N/A |
| Terminated | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cance NCT01913015 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate NCT01807065 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy NCT01953640 | Mayo Clinic | — |
| Completed | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer NCT01812668 | Barbara Ann Karmanos Cancer Institute | N/A |
| Active Not Recruiting | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With NCT01802346 | University of Southern California | N/A |
| Completed | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01503229 | University of Washington | Phase 2 |
| Unknown | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resi NCT01685125 | University of Southern California | Phase 2 |
| Terminated | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated NCT01469338 | University of Southern California | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resis NCT01498978 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer NCT01174199 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer NCT01533246 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tivantinib in Treating Patients With Metastatic Prostate Cancer NCT01519414 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01468532 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Tre NCT01270880 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Saracatinib in Treating Patients With Prostate Cancer NCT01267266 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Ca NCT01240629 | University of Southern California | Phase 1 / Phase 2 |
| Terminated | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistan NCT01145508 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After Firs NCT01253642 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Can NCT01093183 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer NCT01050842 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer NCT01026623 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients Wit NCT00936975 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Re NCT00486642 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy NCT00513071 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer NCT00570700 | University of California, Irvine | Phase 2 |
| Completed | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer NCT01338792 | University of Southern California | Phase 2 |
| Completed | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Re NCT00110214 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer NCT00541281 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy NCT00040755 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer NCT00016107 | National Cancer Institute (NCI) | Phase 2 |